Quinone reductase-mediated nitro-reduction: clinical applications.
作者： Richard J Knox , Shiuan Chen
DOI: 10.1016/S0076-6879(04)82011-1
关键词:
摘要: Publisher Summary This chapter discusses the clinical applications of quinone reductase–mediated nitro-reduction. The reductase enzyme NQO1 catalyzes reduction quinines to their hydroquinone form. has a number unusual properties. It can use either NADPH or NADH with equal activity as cofactor, and it been shown that simple reduced nicotinamide derivatives also act cofactors for this enzyme. examines nitroreductase three enzymes, NQO1, E. coli B and, in particular, NQO2. properties these enzymes are particularly relevant treatment cancer, rationale approach is described chapter. With NQO2, an endogenous human discovered significant bioactivate proven anti-tumor prodrug designated CB 1954. Prodrugs activated by nitro-reduction cancer therapy nitroreductase. describes functional characterization truncated NQO1/NQO2 chimeric preparations. Bioactivation 1954 biodistribution NQO2 humans explained
sci-hub.se 参考文章(90)
Shutsung Liao, John T. Dulaney, H.G. Williams-Ashman, Purification and properties of a flavoprotein catalyzing the oxidation of reduced ribosyl nicotinamide. Journal of Biological Chemistry. ,vol. 237, pp. 2981- 2987 ,(1962) , 10.1016/S0021-9258(18)60260-1
M.T. Huang, G.T. Miwa, N. Cronheim, A.Y. Lu, Rat liver cytosolic azoreductase. Electron transport properties and the mechanism of dicumarol inhibition of the purified enzyme. Journal of Biological Chemistry. ,vol. 254, pp. 11223- 11227 ,(1979) , 10.1016/S0021-9258(19)86473-6
Richard J. Knox, Gene-Directed Enzyme Prodrug Therapy (GDEPT) of Cancer Springer, Boston, MA. pp. 209- 243 ,(1999) , 10.1007/978-1-4615-4823-2_9
Enzyme-prodrug strategies for cancer therapy Kluwer Academic/Plenum Publishers. ,(1999) , 10.1007/978-1-4615-4823-2
Lars Ernster, [56] DT diaphorase Methods in Enzymology. ,vol. 10, pp. 309- 317 ,(1967) , 10.1016/0076-6879(67)10059-1
M T Huang, G T Miwa, A Y Lu, Rat liver cytosolic azoreductase. Purification and characterization. Journal of Biological Chemistry. ,vol. 254, pp. 3930- 3934 ,(1979) , 10.1016/S0021-9258(18)50676-1
Paul Workman, Jane E. Morgan, Kathleen Talbot, Karen A. Wright, Jane Donaldson, Peter R. Twentyman, CB 1954 revisited. II. Toxicity and antitumour activity. Cancer Chemotherapy and Pharmacology. ,vol. 16, pp. 9- 14 ,(1986) , 10.1007/BF00255279
Gillian M. Anlezark, Roger G. Melton, Roger F. Sherwood, Brian Coles, Frank Friedlos, Richard J. Knox, The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochemical Pharmacology. ,vol. 44, pp. 2289- 2295 ,(1992) , 10.1016/0006-2952(92)90671-5
David Siegel, David Ross, Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues11This work is dedicated to the memory of Professor Lars Ernster, who provided us with enthusiastic support, scientific insight, and constant encouragement in our many interactions. Free Radical Biology and Medicine. ,vol. 29, pp. 246- 253 ,(2000) , 10.1016/S0891-5849(00)00310-5
Roger M. Phillips, R.D. Traver, A. de la Cruz, N.W. Gibson, Increased Activity and Expression of NAD(P)H:Quinone Acceptor Oxidoreductase in Confluent Cell Cultures and within Multicellular Spheroids Cancer Research. ,vol. 54, pp. 3766- 3771 ,(1994)